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STEM CELL TRANSPLANTATION (SCT) FOR PATIENTS WITH FAN- 
CONI'S ANEMIA (FA) WITH LOW DOSE CYCLOPHOSPHAMIDE (CY) 
AND ANTITHYMOCYTE GLOBULINS (ATG) WITHOUT THE USE OF 
RADIATION THERAPY, A PROSPECTIVE STUDY 
Ayas, M.F.; Al-J~fii, A.H.; ALMahr, M.; I~lrao~d, M.; Mltstafa, 
M.M.; Mol*,rsa, E.; Shalaby, L.; El-Solb, H. KiJ~g Faisal Specialist Hos- 
pital & Resea~vh Ce,lte'r. Depart77zeJ~t of Pediatric He~tzatology-O*~colo- 
gy, Riyadh, Smldi Arabia. 
Background: Radiation therapy is a risk factor for development 
of secondary malignancy in patients (pts) undergoing SCT for 
aplastic anemia. This risk is higher in FA pts because of their 
defective DNA repair mechanisms. In May 1999, we began a 
prospective study with low dose CY and ATG for conditioning 
FA pts without radiation and report here our results. Patients and 
Methods: From May 1999 through August 2002, 15 pts with FA 
underwent allogeneic SCT at KFSH&RC. Median age was 8.3 
years (range, 5.2-15 years). Diagnosis was confirmed by chromo- 
somal breakage studies with Mitomycin-c and Diepoxybutane 
(DEB). All pts had bone marrow examination before SCT and 
none had evidence of leukemia, myelodysplasia, or any clonal 
abnormalities. All pts had fewer than 12 blood product ransfu- 
sions in the year before BMT. Fourteen donors were HLA-iden- 
tical siblings, and one was an HLA identical father. All donors 
had negative chromosomal breakage studies. Harvested marrows 
were not manipulated, and the median CD 34 dose was 6.6 x 10 ° 
(range, 2.1-24 x 10 <' ) per kg of recipient body weight. The condi 
tioning was with CY 15 mg/kg/day i.v. for 4 days, and ATG 40 
lng/kg i.v. for 4 days. Graft vs. Host disease (GVItD) prophyla~s 
was with Cyclosporin and ATG (20 mg/kg for 6 doses post SCT). 
Donor engraftment was evaluated on day +28 by showing trilin- 
eage engraftment in the bone marrow and by VNTR analysis (for 
same sex SCT) or FISH (for opposite sex SCT) on peripheral 
lymphocytes. Results: All pts engrafted and are now alive and 
transfusion independent with a median follow up time of 15.5 
months (range, 1.2- 41.5 months). Median time to engraftment 
(ANC of > 0.SX10';/L) was 12 days (range, 9-28 days), median 
time to self sustaining platelet count of > 20X10VL was 30 days 
(range, i6-139 days). Three pts developed acute skin GVtID 
(grade 2) and one developed sldn and gut aGVHD(grade 2), all 
pts responded steroids. Thus far, no patients developed chronic 
GVHD. Mncositis grade > 2 developed in all pts. Four patients 
developed hemorrhagic cystitis. Conclusions: Use of radiation can 
be avoided in the conditioning of pts with FA undergoing Allo- 
geneic SCT. Low dose cyclophosphamide at 60 mg/kg with ATG 
can result in good engraftment with reas'onably tolerated to,city. 
45 
PROSPECTIVE MRD MONITORING BY RQ-PCR; CLINICAL FEASIBILITY 
IN EARLY DETECTION AND MANAGEMENT OF CML RELAPSE AFTER 
ALLOGENEIC SCT 
Kiln, D.; Kiln, Y.; Lee, S.; Kiln, t~; H~,a~g, .7.; Khan, C. Catholic 
He~atopoietic Ste~ Cell Trcm,s~h~tatio~z Ce*~ter, The Catholic UMver- 
sity of Korea, Sem,l, So~ttl, Korea. 
Background and Objectives. Immunotherapy at early phase 
relapse after stem cell transplantation (SCT) for chronic mye]ogc- 
nous leukemia (CML) induces ahigher ate of complete remission 
and lower side effects. Real-time quantitative RT-PCR (RQ- 
PCR) has been l~lown to be useful for early detection of CML 
recurrence. However, there has been no consensus about at which 
level RQ-PCR at early period after SCT immunotherapy should 
be given to prevent disease progression. Design and Methods. 
Using RQ-PCR, RT-PCR, and fluorescence in situ hybridization 
(FISH), we prospectively monitored minimal residual disease 
(MRD) in consecutive 45 patients who underwent SCT for CML. 
Patients with quantitative molecular elapse (QMR, rising BCR- 
ABL/ABL>0.01) were randomly assigned to either ,z0 therapy 
(group A) or i~ltTHzHlotherapy (group B) arm. Disease progression to 
molecular cytogenetic relapse (MCR, FISH>5.24%) was com- 
pared between two groups, hnnrunotherapy of immunosuppres- 
sants withdrawal, DLI (CD3+, 1.0 X 10e'/kg), and/or interferon 
was given to patients in group A when disease progressed to 
MCR, as it was given at he time of diagnosis to those in group B 
or initially relapsed MCR Results. 13 patients were diagnosed as 
QMR at a median of 3 months (2.8-6.3 months) post-HSCT. 
MCR occurred in all 6 in group A and 2 of 7 in group B following 
QMR, meanwhile 4 were diagnosed as initial MCR. The probabil- 
ity of MCR was significantly different between two groups (group 
A 100% vs group B 35.7%, P=0.002). Molecular emission (MR) 
was achieved in 11 (64.8%) of 17 patients at a median of 3.3 
months (i.2-11.4 months) after immunotherapy. The probability 
of disease free survival in 11 patients in MR was 87.5%; 10 of 11 
patients remain alive in MR more than 7.5 23.2 months. Acute 
and chronic GVHD developed in 29.4 % and 76.5%, respectively, 
and marrow suppression, on the contrary, did not develop. Treat- 
ment related to,cities developed in 2 patients (11.8%) Interpreta- 
tion and Conclusions. The fact that normalized BCR-ABL trau- 
script rising higher than 0.01 within 6 months after SCT heralded 
disease progression and substantial of the relapsed achieved 
molecular emission after early imlnunotherapy with reduced 
intensity revealed that RQ-PCR is a powerful tool in MRD moni- 
toring and managing CML relapse after SCT. 
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COMPARATIVE OUTCOME OF UNRELATED HEMATOPOIETIC STEM 
CELL TRANSPLANTATION (HSCT) WITH CORD BLOOD (CB) VS BONE 
MARROW (BM) IN PEDIATRIC RECIPIENTS 
Dr//e, j1;  D~wd, 3i.l; 3doghrabi, A.I; Roztsseau, p.2; ~'Vagller, E.l; 
f~tc'lao,~, M.1; Barrette, S. i, Ber'm'teiTz, M.1; Cha'mpa~lze, ,7.i David, 
M.1; De~;lers, ft. ;; ChaT;;pag;;e, AI.A. ; 1. Sai;;te av;;.rti;;e Hospital, ;!/Io;;- 
treal, QC, Ca~ada; 2. Notre Da'nm Hospital, MoTltreal, QC, Cmlada. 
From 06.1996 to 07.2002, 62 unrelated HSCT were undertaken 
in 57 children (36M/22F; median age 7.0 years.) at our institution. 
Stem cell source was CB in 33 and BM in 29. Forty-three patients 
had hematological 1-nalig~lancies and 14 inherited syndromes. HLA- 
A and -B typing was performed by serology for CB and molecularly 
for BM, whereas molecular typing' was used for HLA-DRbl for 
both. Donor-recipient HLA mismatches (MM) were only observed 
in CB-patients: 0 MM=I; 1MM =16; 2MM=16. Time from search 
initiation to HSCT was not differeut in the 2 cohorts, but time from 
decision to HSCT was 36 days shorter in CB recipients (p<0.0001). 
Conditioning regimens included cyclophosphamide with TBI or 
Busulfan _+ VP 16. ATG was administered for 57 transplants. GVt ID 
prophylaxis included cyclosporin + methotrexate for BM-patients, 
and cyclosporin +- steroids _+ methon'exate for CB-patients. Twenty 
CB patients received G-CSF. Supportive care guidelines were iden 
tical in the two groups. Primary graft failure occurred iu 6 CB and 3 
BM HSCT. Acute grade II to IV GVHI) occurred in 5 CB and 1 
BM recipients. Limited cGVHD occurred in 3 CB and 1 BM recipi- 
ents and no patients howed extensive cGVttD. Death occurred in 
12 CB-patients and 11BM patients (multiple organ failure=4 and 5, 
infection=4 and 1, relapse=t~ and 3, and other=l and ~,' respectively)., 
:l'hirty-four children are currently alive, 30 in CR, 3 in relapse and 1 
with autologous reconstitution (IIunter disease). Median time for 
engTaftement, Kaplan-Meicr TRM, OS and EFS are summarized in
table. We conclude that partially HLA-mismatched CB-HSCT is a 
suitable alternative to frilly HLA-lnatched BM-HSCT with no 
increased TRM and comparable outcomes. Consideration should be 
given for earlier selection of CB units for potential recipients. Table 
I summarizes the major clinical end-points: 
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